CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Company Stats
- Market Cap
- $14.1B
- as of Sep 30, 2026
- Enterprise Value
- $16.0B
- Shares Outstanding
- 47.7M
- Free Float
- 92.8%
Income Statement
- Revenue
- $4.0B
- Operating Income
- $25.2M
- Net Income
- -$144.3M
- EBITDA
- $428.5M
- Non-cash Impairment
- $165.0M
- Revenue Growth, 3Y
- 0.3%
- FCF Margin, 3Y Avg
- 11.4%
- FCF Margin, Worst Year
- 8.8%
Cash Flow
- Free Cash Flow
- $518.5M
- FCF Yield
- 3.7%
- Owner FCF Yield
- 3.2%
Balance Sheet
- Cash & Equivalents
- $213.8M
- Total Debt
- $2.1B
- Net Debt
- $1.9B
- Net Debt / EBITDA
- 4.46x
- EV / EBITDA
- 37.33x
- Net Debt / EBIT
- 75.93x
Returns & Capital
- Share Repurchases
- $360.7M
- Buyback Yield, 3Y Avg
- 1.2%
- SBC, 3Y Avg
- $71.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $4.0B | $518.5M | 12.9% |
| FY2024 | $4.0B | $501.6M | 12.4% |
| FY2023 | $4.1B | $365.4M | 8.8% |
| FY2022 | $4.0B | $294.9M | 7.4% |
| FY2021 | $3.5B | $532.0M | 15.0% |
Annual filing data through FY ended December 27, 2025; shares and float as of October 27, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Charles River to Buy Frontage Bioanalysis in $470 Million Cash Deal
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back